$ORIB
Orion Bliss Corp.

2024 Q4 Form 10-Q Financial Statement

#000168316824008588 Filed on December 10, 2024

View on sec.gov

Income Statement

Concept 2024 Q4
Revenue $6.000K
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses
YoY Change
Operating Profit -$906.00
YoY Change -77.37%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income
YoY Change
Income Tax $0.00
% Of Pretax Income
Net Earnings -$906.00
YoY Change -77.37%
Net Earnings / Revenue -15.1%
Basic Earnings Per Share $0.00
Diluted Earnings Per Share $0.00
COMMON SHARES
Basic Shares Outstanding 3.038M shares
Diluted Shares Outstanding 3.038M shares

Balance Sheet

Concept 2024 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $6.191K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $51.69K
YoY Change 5543.12%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $134.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $51.69K
Total Long-Term Assets $134.00
Total Assets $51.83K
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $155.4K
YoY Change 106.2%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $155.4K
Total Long-Term Liabilities
Total Liabilities
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$124.6K
YoY Change 30.54%
Common Stock $304.00
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$103.6K
YoY Change
Total Liabilities & Shareholders Equity $51.83K
YoY Change 5557.75%

Cashflow Statement

Concept 2024 Q4
OPERATING ACTIVITIES
Net Income -$906.00
YoY Change -77.37%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
CY2024Q4 us-gaap Liabilities Current
LiabilitiesCurrent
155429 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
90517 usd
CY2024Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--04-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2025
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001854183
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-10-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
333-257326
dei Entity Registrant Name
EntityRegistrantName
ORION BLISS CORP.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1591444
dei Entity Address City Or Town
EntityAddressCityOrTown
Ashdod
dei Entity Address Address Line1
EntityAddressAddressLine1
Kalonite 9-57
dei Entity Address Country
EntityAddressCountry
IL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
7724233
dei City Area Code
CityAreaCode
307
dei Local Phone Number
LocalPhoneNumber
298 0969
dei Entity Information Former Legal Or Registered Name
EntityInformationFormerLegalOrRegisteredName
N/A                    
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3038000 shares
CY2024Q4 us-gaap Escrow Deposit
EscrowDeposit
6191 usd
CY2024Q2 us-gaap Escrow Deposit
EscrowDeposit
1190 usd
CY2024Q4 us-gaap Intangible Assets Current
IntangibleAssetsCurrent
45500 usd
CY2024Q2 us-gaap Intangible Assets Current
IntangibleAssetsCurrent
0 usd
CY2024Q4 us-gaap Assets Current
AssetsCurrent
51691 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
1190 usd
CY2024Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
134 usd
CY2024Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
134 usd
CY2024Q4 us-gaap Assets
Assets
51825 usd
CY2024Q2 us-gaap Assets
Assets
1324 usd
CY2024Q4 ORIB Accounts Payable Related Party
AccountsPayableRelatedParty
43000 usd
CY2024Q2 ORIB Accounts Payable Related Party
AccountsPayableRelatedParty
37000 usd
CY2024Q4 ORIB Director Loan
DirectorLoan
66929 usd
CY2024Q2 ORIB Director Loan
DirectorLoan
53517 usd
CY2024Q4 us-gaap Notes Payable Current
NotesPayableCurrent
45500 usd
CY2024Q2 us-gaap Notes Payable Current
NotesPayableCurrent
0 usd
CY2024Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3038000 shares
CY2024Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3038000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3038000 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3038000 shares
CY2024Q4 us-gaap Common Stock Value
CommonStockValue
304 usd
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
304 usd
CY2024Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
20656 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
20656 usd
CY2024Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-124564 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110153 usd
CY2024Q4 us-gaap Stockholders Equity
StockholdersEquity
-103604 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-89193 usd
CY2024Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
51825 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1324 usd
CY2024Q4 us-gaap Revenues
Revenues
6000 usd
CY2023Q4 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
6000 usd
us-gaap Revenues
Revenues
0 usd
CY2024Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6906 usd
CY2023Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4003 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20411 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
37626 usd
CY2024Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-906 usd
CY2023Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-4003 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-14411 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-37626 usd
CY2024Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q4 us-gaap Net Income Loss
NetIncomeLoss
-906 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-4003 usd
us-gaap Net Income Loss
NetIncomeLoss
-14411 usd
us-gaap Net Income Loss
NetIncomeLoss
-37626 usd
CY2024Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2024Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2024Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3038000 shares
CY2024Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3038000 shares
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3038000 shares
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3038000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3038000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3038000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3038000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3038000 shares
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-36837 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-33623 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-70460 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-4003 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-74463 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-89193 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-13505 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-102698 usd
CY2024Q4 us-gaap Net Income Loss
NetIncomeLoss
-906 usd
CY2024Q4 us-gaap Stockholders Equity
StockholdersEquity
-103604 usd
us-gaap Net Income Loss
NetIncomeLoss
-14411 usd
us-gaap Net Income Loss
NetIncomeLoss
-37626 usd
us-gaap Increase Decrease In Notes Payable Current
IncreaseDecreaseInNotesPayableCurrent
45500 usd
us-gaap Increase Decrease In Notes Payable Current
IncreaseDecreaseInNotesPayableCurrent
0 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
31089 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37626 usd
us-gaap Payments For Software
PaymentsForSoftware
45500 usd
us-gaap Payments For Software
PaymentsForSoftware
-0 usd
ORIB Proceeds From Accounts Payable Related Party Debt
ProceedsFromAccountsPayableRelatedPartyDebt
6000 usd
ORIB Proceeds From Accounts Payable Related Party Debt
ProceedsFromAccountsPayableRelatedPartyDebt
6000 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
13412 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
24627 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19412 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30627 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
5001 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-6999 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1190 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7781 usd
CY2024Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6191 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
782 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2024Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-124564 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110153 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84E_eus-gaap--UseOfEstimates_zYM8QrLD5JL6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
CY2024Q4 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zkUpMt0Scc8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Risks and Uncertainties</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2020, a novel strain of coronavirus (COVID-19) emerged in Wuhan, Hubei Province, China. While initially the outbreak was largely concentrated in China and caused significant disruptions to its economy, it has now spread to several other countries and infections have been reported globally.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time but is anticipated to have a material adverse impact on our business, financial condition and results of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management expects that its business will be impacted to some degree, but the significance of the impact of the COVID-19 outbreak on the Company’s business and the duration for which it may have an impact cannot be determined at this time.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zYGEAIcjm3Oi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Financial Statement Reclassification</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain account balances from prior periods have been reclassified in these financial statements to conform to current period classifications.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2024Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2024Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3038000 shares
CY2024Q4 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-190 usd
CY2024Q4 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
190 usd
CY2024Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
26158 usd
CY2024Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
26158 usd
CY2024Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2024Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
124564 usd
CY2024Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001683168-24-008588-index-headers.html Edgar Link pending
0001683168-24-008588-index.html Edgar Link pending
0001683168-24-008588.txt Edgar Link pending
0001683168-24-008588-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
obliss_ex3101.htm Edgar Link pending
obliss_ex3201.htm Edgar Link pending
obliss_i10q103124.htm Edgar Link pending
orib-20241031.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
orib-20241031_def.xml Edgar Link unprocessable
orib-20241031_cal.xml Edgar Link unprocessable
orib-20241031_lab.xml Edgar Link unprocessable
orib-20241031_pre.xml Edgar Link unprocessable
obliss_i10q103124_htm.xml Edgar Link completed
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending